Inactive Instrument

Diaxonhit SA Stock Euronext Paris

Equities

ALEHT

FR0013240934

Biotechnology & Medical Research

End-of-day quote Euronext Paris
- EUR - Intraday chart for Diaxonhit SA
Sales 2023 130M 141M Sales 2024 * 138M 150M Capitalization 153M 166M
Net income 2023 4M 4.34M Net income 2024 * 9M 9.77M EV / Sales 2023 1.29 x
Net Debt 2023 * 23M 24.98M Net cash position 2024 * 9.9M 10.75M EV / Sales 2024 * 1.04 x
P/E ratio 2023
38.3 x
P/E ratio 2024 *
15.8 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 61.3%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer - 17-06-18
Director of Finance/CFO 43 22-09-30
Chief Operating Officer - -
Members of the board TitleAgeSince
Chief Executive Officer - 17-06-18
Director/Board Member 68 09-11-03
Director/Board Member 67 17-06-14
More insiders
Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The group has approximately 320 employees, three production units based in the Paris region, in Germany and in the United States, and subsidiaries in Milan in Italy, Dorking in the United Kingdom, Sissach in Switzerland, Bünde in Germany and Utrecht in the Netherlands.
Calendar
More about the company